satsuma
pharmaceuticals
announces
topline
results
emerge
phase
trial
acute
treatment
migraine
topline
data
show
statistically
significant
differences
either
dosage
strength
placebo
endpoints
freedom
pain
bothersome
symptom
two
hours
trial
low
adverse
event
rates
serious
adverse
events
reported
analyses
emerge
trial
data
ongoing
satsuma
expects
provide
detailed
update
business
plans
analyses
completed
south
san
francisco
globe
newswire
pharmaceuticals
nasdaq
stsa
biopharmaceutical
company
today
announced
topline
results
phase
emerge
efficacy
trial
dihydroergotamine
dhe
nasal
powder
acute
treatment
migraine
although
topline
data
showed
numerical
differences
favor
mg
mg
versus
placebo
endpoints
freedom
pain
freedom
bothersome
symptom
among
photophobia
phonophobia
nausea
two
hours
differences
achieve
statistical
significance
either
dosage
strength
dosage
strengths
however
demonstrate
significant
effects
freedom
pain
bothersome
symptom
three
hours
later
time
points
dosage
strengths
emerge
trial
low
adverse
event
rates
serious
adverse
events
reported
john
kollins
president
chief
executive
officer
satsuma
commented
surprised
disappointed
achieve
statistical
significance
endpoints
emerge
trial
behalf
everyone
satsuma
like
thank
many
people
migraine
participated
emerge
well
staff
trial
sites
dedication
diligence
completing
trial
despite
challenges
posed
ongoing
analysis
emerge
trial
data
ongoing
satsuma
expects
provide
detailed
update
business
plans
analyses
completed
june
company
cash
cash
equivalents
marketable
securities
million
emerge
trial
phase
emerge
efficacy
trial
randomized
parallel
group
study
migraine
patients
conducted
united
states
emerge
study
designed
accordance
fda
recommendations
outlined
fda
guidance
migraine
developing
drugs
acute
treatment
february
establishing
full
eligibility
emerge
trial
participants
randomized
receive
one
three
treatments
dhe
mg
dhe
mg
matching
placebo
instructed
treat
next
migraine
attack
least
moderate
pain
severity
allocated
blinded
study
medication
two
endpoints
emerge
trial
freedom
pain
freedom
bothersome
symptom
among
photophobia
phonophobia
nausea
assessed
two
hours
administration
study
medication
trial
statistically
designed
greater
power
freedom
pain
endpoint
greater
power
freedom
bothersome
symptom
endpoint
addition
emerge
trial
design
incorporated
number
secondary
endpoints
prospective
evaluations
clinical
performance
number
patient
subgroups
satsuma
pharmaceuticals
satsuma
pharmaceuticals
biopharmaceutical
company
developing
novel
therapeutic
product
acute
treatment
migraine
combination
proprietary
formulation
dihydroergotamine
mesylate
dhe
quickly
easily
proprietary
nasal
delivery
device
developing
satsuma
applied
proprietary
nasal
drug
delivery
formulation
engineered
drug
particle
technologies
create
compact
dhe
product
rapidly
matter
seconds
satsuma
headquartered
south
san
francisco
california
operations
california
research
triangle
park
north
carolina
information
please
visit
cautionary
note
statements
press
release
contains
statements
concerning
business
operations
financial
performance
condition
satsuma
pharmaceuticals
company
well
company
plans
objectives
expectations
business
operations
financial
performance
condition
statements
include
limited
statements
company
expectations
regarding
future
business
plans
company
actual
results
could
differ
materially
stated
implied
statements
due
number
factors
including
limited
risks
detailed
company
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
well
documents
may
filed
company
time
time
place
undue
reliance
statements
statements
speak
date
made
company
undertakes
obligation
update
revise
publicly
statements
whether
result
new
information
future
events
otherwise
press
release
discusses
product
candidate
clinical
development
yet
approved
marketing
food
drug
administration
representation
made
safety
effectiveness
therapeutic
use
studied
investor
corporate
contacts
corey
davis
phd
lifesci
advisors
llc
cdavis
